Today: 2 July 2026
Browse Category

NYSE:LLY 1 February 2026 - 9 February 2026

Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

New York, Feb 8, 2026, 10:09 EST — The market is shut. Eli Lilly will take the spotlight Monday as Wall Street reopens, after Hims & Hers announced it’s pulling its compounded weight-loss pill in response to a U.S. Food and Drug Administration warning. Lilly's shares closed Friday at $1,058.18, rising 3.7%. “No one should be mass-compounding or selling knockoff GLP-1 products regardless of how they’re administered,” a Lilly spokesperson said.
8 February 2026
···
Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

New York, Feb 6, 2026, 17:39 EST — Trading after the bell. Eli Lilly jumped 3.7% to $1,058.18 in late trading Friday after U.S. regulators moved to clamp down on GLP-1 ingredients in unapproved compounded drugs. The Department of Health and Human Services’ general counsel also referred Hims & Hers, a telehealth firm, to the Justice Department for investigation; Hims tumbled almost 12% postmarket.
7 February 2026
···
Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

New York, Feb 6, 2026, 10:53 EST — Regular session Eli Lilly and Company shares climbed about 3% on Friday, recovering part of Thursday’s steep 8% drop. The rebound came after the U.S. Food and Drug Administration indicated it would crack down on illegal copycat weight-loss drugs. The stock traded up 3% at $1,051.74. FDA Commissioner Marty Makary emphasized the agency cannot vouch for the “quality, safety or effectiveness” of these non-approved medicines.
6 February 2026
····
Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

New York, Feb 6, 2026, 08:45 EST — Premarket Shares of Hims & Hers Health dropped 3.8% to $23.48 in premarket trading on Friday. The slide came after FDA Commissioner Marty Makary warned the agency would act quickly against firms mass-marketing “illegal copycat drugs.” The stock had already fallen 3.8% on Thursday and plunged nearly 10% after hours, following Makary’s post on X stating, “The FDA cannot verify the quality, safety, or effectiveness of non-approved drugs.” His comments came after Hims introduced a compounded version of Novo Nordisk’s Wegovy weight-loss medication.
6 February 2026
····
Stock Market Today: S&P 500 futures steady after tech slump as Alphabet AI spending rattles investors

Stock Market Today: S&P 500 futures steady after tech slump as Alphabet AI spending rattles investors

New York, Feb 5, 2026, 05:58 EST — Premarket U.S. stock index futures showed a mixed picture early Thursday following a sharp tech sell-off. Nasdaq 100 futures ticked up 0.13%, while Dow futures fell 0.20%, and S&P 500 futures inched down 0.01%. These contracts trade before the cash market opens and often hint at Wall Street's initial direction.
5 February 2026
···
Eli Lilly stock price jumps 10% after-hours on upbeat 2026 forecast and Q4 beat

Eli Lilly stock price jumps 10% after-hours on upbeat 2026 forecast and Q4 beat

New York, Feb 4, 2026, 16:42 EST — After-hours Eli Lilly shares surged roughly 10.4% to $1,107.12 in after-hours trading Wednesday following a robust fourth-quarter report and a 2026 profit forecast that topped Wall Street estimates. During the regular session, the stock fluctuated between $995.88 and $1,114, with around 7.1 million shares changing hands.
4 February 2026
··
Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Copenhagen, Feb 4, 2026, 16:49 — Regular session Shares of Novo Nordisk plunged roughly 16% in Copenhagen on Wednesday after the Wegovy maker warned that sales and profits could dip in 2026 amid renewed pressure on U.S. drug prices. Jyske Bank analysts described the revised outlook as “yet another blow” for investors. In New York, the company’s ADRs dropped $1.94, or about 3.9%, to $48.36.
4 February 2026
···
Eli Lilly (LLY) stock price jumps 10% after 2026 outlook; pricing pressure and FDA decision in focus

Eli Lilly (LLY) stock price jumps 10% after 2026 outlook; pricing pressure and FDA decision in focus

New York, Feb 4, 2026, 11:01 EST — Regular session Eli Lilly and Company shares surged about 10% Wednesday after the company released its quarterly earnings and 2026 outlook, sparking renewed enthusiasm for its weight-loss division. The stock climbed to $1,104.94 in late-morning New York trading, bouncing back from a low of $995.88 earlier in the session.
4 February 2026
··
Dow Jones today: Dow edges higher as Lilly, Super Micro cushion Wall Street after AI software rout

Dow Jones today: Dow edges higher as Lilly, Super Micro cushion Wall Street after AI software rout

New York, February 4, 2026, 10:04 ET — Regular session The Dow Jones Industrial Average edged higher early on Wednesday, lifted by upbeat results from Eli Lilly and Super Micro Computer, while investors stayed cautious on software and cloud stocks after a sharp selloff a day earlier. At 09:30 a.m. ET, the Dow rose 175.92 points, or 0.40%, to 49,439.32; the S&P 500 was up 0.04% and the Nasdaq Composite fell 0.27%.
4 February 2026
··
Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

New York, February 3, 2026, 18:04 EST — Trading after the close. Eli Lilly and Company shares dropped 3.9%, closing at $1,003.46 on Tuesday, then held steady in after-hours trading. Novo Nordisk’s U.S.-listed shares plunged 14%, after it forecast a steeper sales decline than expected for 2026, weighing on the obesity-drug sector. Pfizer also slipped following new weight-loss drug data. “Novo’s showing there’s a market for oral options,” noted Citizens analyst Jonathan Wolleben.
4 February 2026
····
1 2 3 4 5 … 13

Stock Market Today

  • AI and Chip Stocks Fall as Market Takes a Hit
    July 2, 2026, 7:27 AM EDT. AI and semiconductor shares dropped, putting pressure on the wider market. Chip names, key plays in tech and AI, are usually seen as a market sentiment gauge. If losses keep up in these sectors, it could point to deeper worries for investors and shake confidence more broadly.
Go toTop